SUMMARY In order to test the hypothesis that serum ferritin below 60 [ig/l is a good indicator of iron deficiency in patients with rheumatoid arthritis peroral iron was given to 67 patients with active rheumatoid arthritis over a three month period. A rise in haemoglobin concentration was taken as evidence of iron responsive anaemia. In anaemic patients serum ferritin below 60 [ig/l was a good indicator of iron responsive anaemia, with a predictive value of 83%. Although high plasma transferrin and low mean cell volume showed similar predictive values, more patients with iron deficiency anaemia could be diagnosed by serum ferritin measurements than by other conventional blood tests. In contrast, the predictive value of serum ferritin above 60 p.g/l was low (50%). The test was of no predictive value in non-anaemic patients. In patients with anaemia and active rheumatoid arthritis serum ferritin is the best blood test currently available for the prediction of iron responsive anaemia.
In patients with active rheumatoid arthritis (RA) anaemia may be caused by the 'anaemia of chronic disorders' and iron deficiency. The differential diagnosis between these two types of anaemia is potentially important but may be extremely difficult unless bone marrow smears stained for iron are examined. The main reason for the difficulty is that the usual blood tests indicating iron deficiency (mean cell volume (MCV), mean corpuscular haemoglobin concentration (MCHC), serum iron) are affected similarly in the two types of anaemia. The magnitude of the problem is due to the fact that practically all patients with RA of a certain disease activity develop the anaemia of chronic disorders and up to 75% of the same patients also have iron deficiency.1 2 Serum ferritin is a good indicator of iron stores in the organism and is valuable in the diagnosis of iron deficiency anaemia. Since it is also an acute phase reactant it might a priori be of dubious value in RA.
In a previous study we showed that in patients with anaemia and RA serum ferritin levels below 60
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Results
The predictive values of the laboratory variables for changes in Hb in anaemic patients are given in Table  1 ; all changes in Hb were included. Serum ferritin <60 ig/l predicted an increase in Hb during iron therapy in 83% (19/23) of the patients, while Hb decreased in 50% (6/12) of the patients with serum ferritin >60 ig/l (p<0 01). In non-anaemic patients serum ferritin had no predictive value. Hb increased in 61% (11/18) of the patients with serum ferritin <60 [ig/l and decreased in 40% (4/10) of patients with serum ferritin , 60 ,ug/l (p> 0-05). In four patients with serum ferritin <60 ,ug/l the Hb was unchanged during iron therapy.
The results from the individual patients are given in Tables 2a, b , and c. In Table 3 are given the group means and SEM. There was no difference in serum ferritin between anaemic and non-anaemic patients, but serum ferritin increased during iron therapy. In the anaemic patients MCHC, serum iron, and plasma transferrin were lower than in non-anaemic patients, and ESR and CRP were higher. During iron therapy there was a decrease in plasma transferrin in both anaemic and non-anaemic patients. There was no change in the overall disease activity as judged by an unchanged ESR and CRP during the three months.
Discussion
This study has shown that in anaemic patients with RA serum ferritin levels below 60 ig/l indicate iron responsive anaemia with a rather high degree of accuracy (83%). Although MCV and plasma transferrin scored comparably high percentages, it is evident from Table 1 that serum ferritin would diagnose more patients with iron deficiency anaemia than any other blood test. If the simultaneous presence of low serum ferritin and high plasma transferrin were taken as evidence of iron deficiency anaemia, the predictive value would be further increased (to 91%), but again with a loss of the number of patients correctly defined as having iron deficient anaemia. None of the tests were of any value in predicting a negative response to iron therapy, and although low serum ferritin levels were found in several patients in the non-anaemic group, the predictive value was too low to be of any clinical value in predicting a rise in Hb concentration in this group of patients.
These results support our previous data which showed that serum ferritin was a good indicator of iron deficiency as assessed by bone marrow examination and further defined the clinical applicability of this blood test in terms of its ability to predict iron responsive anaemia in these patients.3 These results and those reported by others2 4 show that serum ferritin is the best blood test for evaluating the iron status in patients with RA. It needs to be considered whether it should replace bone marrow examination in this context.
It is not completely clear why serum ferritin values above 60 ,ug/l could not predict a negative outcome of iron therapy. It must be appreciated, however, that the reference value used in this work, viz a rise in Hb concentration after iron therapy, may not be quite fair to the test, since a change in disease activity during the three months of iron treatment may also influence the Hb concentration in the individual patients. Actually, in five of the six patients who in spite of high serum ferritin values showed an increase in Hb concentration (data are missing for the sixth patient) disease activity decreased as judged from decreasing values for CRP, and consequently the recording of these patients as a failure regarding the predictive value of a high serum ferritin for no Hb response to iron therapy may not be correct. The strength of the design of this study is that it was shown that a low serum ferritin value could predict a positive outcome of iron therapy despite the presence of confounding factors influencing the Hb concentration in these patients. Seventy five per cent of the anaemic patients and 50% of the non-anaemic patients showed a rise in Hb concentration after three months of iron therapy, and 87% of all patients showed an increase in serum ferritin values. Also a significant decrease in plasma transferrin values after treatment was noted (Table 3 ). This indicates that functional iron deficiency and iron deficiency anaemia were extremely common in our patients, in agreement with previous experience.t-3 It also indicates that peroral iron is readily absorbed in these patients, despite the simultaneous presence of the anaemia of chronic disorders, which is believed to be associated with a decrease of iron absorption from the intestines. 6 The fact that no test could predict which of the nonanaemic patients would show an increase in Hb concentration is probably due to the fact that iron deficient erythropoiesis was not prominent in these latter patients. Thus they had normal values for MCV and MCHC and no significant increase in Hb concentration after treatment (Table 3) . This interpretation of our finding is not necessarily at variance with that of Bentley and Williams, who demonstrated a transient rise in Hb after parenteral iron treatment of patients with RA and anaemia.7 They suggested that patients with RA may, as a rule, not be iron deficient. but that a relative iron deficiency in the bone marrow may exist due to excessive entrapment of iron in the inflamed synovial membrane.
In our previous study we found no correlation between serum ferritin and plasma fibrinogen, and in the present study no correlation between serum ferritin and CRP could be shown. It thus seems quite well documented that serum ferritin is not a conventional acute phase reactant, though it is increased in active RA per se. These findings constitute the basis for our proposal that serum ferritin levels below 60 stg/l may be used as a cut off point indicating iron deficiency in patients with RA regardless of the disease activity. This value is five times higher than the usual lower limit of serum ferritin indicating iron deficiency." The peculiar role of serum ferritin, which is increased in active disease but does not follow the conventionally used parameters of disease activity, calls for further studies of the pathophysiology of serum ferritin in active RA.
